Q1 2018 13F Holders as of 31 Mar 2018
-
Type / Class
-
Debt / NOTE 0.750% 8/1
-
Market price (% of par)
-
218.94%
-
Total 13F principal
-
$229,681,000
-
Principal change
-
-$13,626,000
-
Total reported market value
-
$503,037,000
-
Number of holders
-
17
-
Value change
-
-$8,237,722
-
Number of buys
-
9
-
Number of sells
-
11
Institutional Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 as of Q1 2018
As of 31 Mar 2018,
LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 was held by
17 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$229,681,000
in principal (par value) of the bond.
The largest 10 bondholders included
CITADEL ADVISORS LLC, Polygon Management Ltd., WOLVERINE ASSET MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, CALAMOS ADVISORS LLC, ANGELO GORDON & CO., L.P., Allianz Asset Management GmbH, CSS LLC/IL, PIPER JAFFRAY & CO., and GOLDMAN SACHS GROUP INC.
This page lists
17
institutional bondholders reporting positions
for the Q1 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.